Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maraviroc.

Natalie J Carter1, Gillian M Keating

  • 1Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 12, 2007
PubMed
Summary
This summary is machine-generated.

Maraviroc effectively reduces viral load and increases CD4+ cell counts in patients with R5-tropic HIV-1. This CCR5 antagonist demonstrated significant efficacy and good tolerability in clinical trials for treatment-experienced individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ancestry-specific hereditary cancer panel yields: Moving toward more personalized risk assessment.

Journal of genetic counseling·2020
Same author

Age-adjusted association of homologous recombination genes with ovarian cancer using clinical exomes as controls.

Hereditary cancer in clinical practice·2019
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels.

Genetics in medicine : official journal of the American College of Medical Genetics·2018
Same author

Germline pathogenic variants identified in women with ovarian tumors.

Gynecologic oncology·2018
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Area of Science:

  • Immunology
  • Virology
  • Pharmacology

Background:

  • Maraviroc is a small-molecule CCR5 receptor antagonist.
  • CCR5 is a coreceptor for HIV-1 entry into host cells.
  • Maraviroc inhibits HIV-1 entry by blocking CCR5.

Purpose of the Study:

  • To evaluate the efficacy and safety of maraviroc in treatment-experienced patients with R5-tropic HIV-1.
  • To assess maraviroc's impact on viral load and CD4+ cell counts.

Main Methods:

  • Two large, randomized, placebo-controlled phase IIb/III trials (MOTIVATE-1 and MOTIVATE-2).
  • Patients received maraviroc (150 or 300mg twice daily) plus optimized background therapy (OBT) or placebo plus OBT.
  • Data analyzed at 24 and 48 weeks.

Related Experiment Videos

Main Results:

  • Significantly greater reduction in HIV-1 viral load in maraviroc plus OBT group compared to placebo plus OBT.
  • Higher proportion of patients achieved HIV-1 RNA levels <400 and <50 copies/mL with maraviroc.
  • Significant increase in CD4+ cell count observed with maraviroc plus OBT.

Conclusions:

  • Maraviroc plus OBT demonstrated significant efficacy in reducing viral load and improving CD4+ cell counts in treatment-experienced patients with R5-tropic HIV-1.
  • Maraviroc was generally well-tolerated at dosages up to 300mg twice daily.